Epiregulin (EPR) is a member of the EGF family of growth factors that is primarily expressed in the placenta and macrophages. High levels of expression have been detected in various carcinomas. Epiregulin also stimulates the proliferation of fibroblasts, smooth muscle cells, and hepatocytes, and has been shown to inhibit the growth of several epithelial tumor cells. Epiregulin has been implicated in the implantation process during pregnancy.
Swiss-Prot Accession Number: O14944
A leading global drug discovery and development laboratory, IQVIA Laboratories (the laboratory business of IQVIA) provides customers with a comprehensive assemblage of solutions encompassing central laboratory and specialty biomarker services including genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME and bioanalytical along with extensive offerings in antibody drug discovery, biomarker discovery, and decentralized clinical trial lab solutions.
Learn more at labs.iqvia.com
Copyright 2025 Rules-Based Medicine. All rights reserved. RBM does not sell your personal information.